James P. Dean

3.0k total citations · 3 hit papers
59 papers, 1.8k citations indexed

About

James P. Dean is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, James P. Dean has authored 59 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Genetics, 36 papers in Pathology and Forensic Medicine and 21 papers in Hematology. Recurrent topics in James P. Dean's work include Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (36 papers) and Chronic Myeloid Leukemia Treatments (20 papers). James P. Dean is often cited by papers focused on Chronic Lymphocytic Leukemia Research (49 papers), Lymphoma Diagnosis and Treatment (36 papers) and Chronic Myeloid Leukemia Treatments (20 papers). James P. Dean collaborates with scholars based in United States, Italy and Spain. James P. Dean's co-authors include Thomas J. Kipps, Carol Moreno, Jan A. Burger, Paul M. Barr, Steven Coutré, Peter Hillmen, Susan O’Brien, Sandra Dai, Paolo Ghia and Alessandra Tedeschi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

James P. Dean

51 papers receiving 1.8k citations

Hit Papers

Long-term efficacy and safety of first-line ibrutinib tre... 2019 2026 2021 2023 2019 2019 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
    2019 312 citations Jan A. Burger, Paul M. Barr et al. Leukemia profile →
  2. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
    2019 307 citations Susan O’Brien, Jacqueline C. Barrientos et al. profile →
  3. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
    2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers

James P. Dean
Karim Maloum France
Kerry A. Rogers United States
Liana Gercheva Bulgaria
Lorenzo Falchi United States
Priti Patel United States
Joanna Góra‐Tybor Poland
Nikolaos Anagnostopoulos Greece
Kirsten Meid United States
Cheson Bd United States
Sara Rodríguez United States
Karim Maloum France
James P. Dean
Citations per year, relative to James P. Dean James P. Dean (= 1×) peers Karim Maloum

Countries citing papers authored by James P. Dean

Since Specialization
Citations

This map shows the geographic impact of James P. Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James P. Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James P. Dean more than expected).

Fields of papers citing papers by James P. Dean

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James P. Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James P. Dean. The network helps show where James P. Dean may publish in the future.

Co-authorship network of co-authors of James P. Dean

This figure shows the co-authorship network connecting the top 25 collaborators of James P. Dean. A scholar is included among the top collaborators of James P. Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James P. Dean. James P. Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2025). Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 146(18). 2168–2176. 5 indexed citations
2.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2025). Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. 26(2). 200–213. 9 indexed citations
3.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2024). CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S342–S343. 4 indexed citations
4.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2024). Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.. Journal of Clinical Oncology. 42(16_suppl). 7007–7007. 4 indexed citations
5.
6.
Jurczak, Wojciech, Michael Wang, Marek Trněný, et al.. (2024). Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study. Clinical Lymphoma Myeloma & Leukemia. 24. S226–S226.
7.
8.
Chong, Elise A., Junichiro Yuda, Koji Izutsu, et al.. (2024). A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.. Journal of Clinical Oncology. 42(16_suppl). TPS7091–TPS7091. 3 indexed citations
9.
Woyach, Jennifer A., Paolo Ghia, John C. Byrd, et al.. (2023). B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clinical Cancer Research. 29(16). 3065–3073. 7 indexed citations
10.
Ghia, Paolo, John N. Allan, Tanya Siddiqi, et al.. (2023). FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY. Hematological Oncology. 41(S2). 238–239. 1 indexed citations
11.
Wang, Michael, Wojciech Jurczak, Marek Trněný, et al.. (2023). Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood. 142(Supplement 2). LBA–2. 13 indexed citations
12.
Moreno, Carol, Constantine S. Tam, Andrew Grigg, et al.. (2023). Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Advances. 7(18). 5294–5303. 10 indexed citations
13.
Jain, Nitin, Lisa J. Croner, John N. Allan, et al.. (2023). Absence of BTK , BCL2 , and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical Cancer Research. 30(3). 498–505. 20 indexed citations
14.
Mar, Nataliya, Yousef Zakharia, Alejandro Falcón, et al.. (2023). Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers. 15(11). 2978–2978. 1 indexed citations
15.
Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →
16.
Byrd, John C., Richard R. Furman, Steven Coutré, et al.. (2020). Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical Cancer Research. 26(15). 3918–3927. 126 indexed citations
17.
Ahn, Inhye E., Xin Tian, David Ipe, et al.. (2020). Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of Clinical Oncology. 39(6). 576–585. 56 indexed citations
18.
Blum, Lisa K., Thomas J. Kipps, Jan A. Burger, et al.. (2020). Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 97. 106432–106432. 57 indexed citations
19.
Burger, Jan A., Paul M. Barr, Tadeusz Robak, et al.. (2019). Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 34(3). 787–798. 312 indexed citations breakdown →
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karim Maloum Breakdown of academic impact, for papers by Kerry A. Rogers Breakdown of academic impact, for papers by Liana Gercheva Breakdown of academic impact, for papers by Lorenzo Falchi Breakdown of academic impact, for papers by Priti Patel Breakdown of academic impact, for papers by Joanna Góra‐Tybor Breakdown of academic impact, for papers by Nikolaos Anagnostopoulos Breakdown of academic impact, for papers by Kirsten Meid Breakdown of academic impact, for papers by Cheson Bd Breakdown of academic impact, for papers by Sara Rodríguez
Rankless by CCL
2026